Palisade Bio (NASDAQ:PALI) Director Buys $49,000.00 in Stock

Posted by Francis Steltz on Jul 13th, 2026

Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) Director Robert Jr. Baltera acquired 25,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were acquired at an average price of $1.96 per share, with a total value of $49,000.00. Following the acquisition, the director owned 461,904 shares in the company, valued at approximately $905,331.84. The trade was a 5.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Robert Jr. Baltera also recently made the following trade(s):

On Wednesday, July 8th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The shares were acquired at an average price of $1.99 per share, for a total transaction of $39,800.00.
On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $60,900.00.
On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was acquired at an average price of $2.05 per share, with a total value of $41,000.00.
On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $1.98 per share, with a total value of $19,800.00.
On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were acquired at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Price Performance

PALI opened at $1.96 on Monday. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.85. The company has a market cap of $340.22 million, a P/E ratio of -1.94 and a beta of 1.50. The firm’s 50-day moving average price is $1.92 and its 200-day moving average price is $1.92.

Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, research analysts anticipate that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Palisade Bio

Several hedge funds have recently added to or reduced their stakes in PALI. Perceptive Advisors LLC purchased a new position in shares of Palisade Bio during the 4th quarter valued at about $28,318,000. Commodore Capital LP purchased a new stake in shares of Palisade Bio in the fourth quarter worth about $26,896,000. Janus Henderson Group PLC grew its holdings in Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after acquiring an additional 149,118 shares during the period. Octagon Capital Advisors LP raised its position in Palisade Bio by 7.4% during the first quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock valued at $17,984,000 after acquiring an additional 708,419 shares in the last quarter. Finally, RA Capital Management L.P. purchased a new position in Palisade Bio during the fourth quarter valued at approximately $16,742,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Oppenheimer set a $7.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Finally, LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.83.

Get Our Latest Stock Report on PALI

About Palisade Bio

(Get Free Report)

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.